1-11 of 11
Steve Weitman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract #2909: Brostallicin context of vulnerabilities revealed through HT-RNAi based cellular pharmacogenomics

Holly Yin, Jeffrey Kiefer, Chris Sereduk, Pinar Tuzmen, Kandavel Shanmugam, Shannon Shulby, Steve Weitman, Daniel Von Hoff, Spyro Mousses, Elizabeth Bruckheimer
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2909.
Published: 01 May 2009
View articletitled, Abstract #2909: Brostallicin context of vulnerabilities revealed through HT-RNAi based cellular pharmacogenomics
Journal Articles

Abstract #2711: Structurally unique Na+/K+-ATPase antagonist UNBS1450: the first hemi-synthetic cardenolide with marked anti-tumor activity to enter clinical trials

Tatjana Mijatovic, Eric Van Quaquebeke, Frank Van Vynckt, Steve Weitman, Robert Kiss
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2711.
Published: 01 May 2009
View articletitled, Abstract #2711: Structurally unique Na+/K+-ATPase antagonist UNBS1450: the first hemi-synthetic cardenolide with marked anti-tumor activity to enter clinical trials
Journal Articles

Application of cellular pharmacogenomics and systems biology to identify contexts of vulnerability and guide the clinical development of Brostallicin

Jeffrey Kiefer, Kandavel Shanmugam, Steve Weitman, Holly Yin, Donald Chow, Chris Sedurik, Patrick Shannon, Robert MacArthur, Daniel Von Hoff, Spyro Mousses, Elizabeth Bruckheimer
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 920.
Published: 01 May 2008
View articletitled, Application of cellular pharmacogenomics and systems biology to identify contexts of vulnerability and guide the clinical development of Brostallicin
Journal Articles

Comparative human tumor xenograft studies of docetaxel encapsulated with azaya therapeutics protein stabilized liposome (PSLTM) nanotechnology (ATI-1123) and standard docetaxel

Michael Wick, Wesley Lowell, Scott Kelly, Mario Sepulveda, Jennifer Marty, Chris Takimoto, Jeffrey Kahl, Chandra Singh, Michael Dwyer, Steve Weitman
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 2255.
Published: 01 May 2007
View articletitled, Comparative human tumor xenograft studies of docetaxel encapsulated with azaya therapeutics protein stabilized liposome (PSLTM) nanotechnology (ATI-1123) and standard docetaxel
Journal Articles

Tasidotin HCl (formerly ILX651), a tubulin-binding dolastatin-15 analog, demostrates a wide spectrum of In Vivo antitumor activity

Larry Arthaud, Katherine Martinez, Stephanie Roth, Roy Krumbholz, Murray Stackhouse, Steve Weitman
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1383.
Published: 01 May 2005
View articletitled, Tasidotin HCl (formerly ILX651), a tubulin-binding dolastatin-15 analog, demostrates a wide spectrum of In Vivo antitumor activity
Journal Articles

In vivo antitumor effect of Tasidotin HCl (formerly ILX651), a dolastatin-15 analog with a novel mechanism of action, against the PANC-1 and MiaPaCa human pancreatic tumor xenograft models

Larry Arthaud, Stephanie Roth, Roy Krumbholz, Steve Weitman
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1389.
Published: 01 May 2005
View articletitled, In vivo antitumor effect of Tasidotin HCl (formerly ILX651), a dolastatin-15 analog with a novel mechanism of action, against the PANC-1 and MiaPaCa human pancreatic tumor xenograft models
Journal Articles

Antitumor Activity of a Kinesin Inhibitor

Roman Sakowicz, Jeffrey T. Finer, Christophe Beraud, Anne Crompton, Evan Lewis, Alex Fritsch, Yan Lee, John Mak, Robert Moody, Rebecca Turincio, John C. Chabala, Paul Gonzales, Stephanie Roth, Steve Weitman, Kenneth W. Wood
Journal: Cancer Research
Cancer Res (2004) 64 (9): 3276–3280.
https://doi.org/10.1158/0008-5472.CAN-03-3839
Published: 03 May 2004
View articletitled, Antitumor Activity of a Kinesin Inhibitor
Open the PDF for Antitumor Activity of a Kinesin Inhibitor in another window
Includes: Supplementary data
Journal Articles

In vivo and in vitro antitumor effects of ILX651, a pentapeptide with anovel mechanism of action.

Stephanie Roth, Roy Krumbholz, Larry Arthaud, Steve Weitman, Katherine Stephenson
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 488.
Published: 01 April 2004
View articletitled, In vivo and in vitro antitumor effects of ILX651, a pentapeptide with anovel mechanism of action.
Journal Articles

ILX651 disrupts microtuble assembly by two mechanisms

Katherine Stephenson, Veena Prasad, Steve Weitman, Richard F. Ludena
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1297.
Published: 01 April 2004
View articletitled, ILX651 disrupts microtuble assembly by two mechanisms
Journal Articles

Water Soluble 20(S)-Glycinate Esters of 10,11-Methylenedioxycamptothecins Are Highly Active against Human Breast Cancer Xenografts

Randy M. Wadkins, Philip M. Potter, Bogdan Vladu, Jennifer Marty, Gina Mangold, Steve Weitman, Govindarajan Manikumar, Mansukh C. Wani, Monroe E. Wall, Daniel D. Von Hoff
Journal: Cancer Research
Cancer Res (1999) 59 (14): 3424–3428.
Published: 15 July 1999
View articletitled, Water Soluble 20(S)-Glycinate Esters of 10,11-Methylenedioxycamptothecins Are Highly Active against Human Breast Cancer Xenografts
Open the PDF for Water Soluble 20(S)-Glycinate Esters of 10,11-Methylenedioxycamptothecins Are Highly Active against Human Breast Cancer Xenografts in another window
Journal Articles

Enhanced Antitumor Activity of 6-Hydroxymethylacylfulvene in Combination with Irinotecan and 5-Fluorouracil in the HT29 Human Colon Tumor Xenograft Model

Carolyn D. Britten, Susan G. Hilsenbeck, S. Gail Eckhardt, Jennifer Marty, Gina Mangold, John R. MacDonald, Eric K. Rowinsky, Daniel D. Von Hoff, Steve Weitman
Journal: Cancer Research
Cancer Res (1999) 59 (5): 1049–1053.
Published: 01 March 1999
View articletitled, Enhanced Antitumor Activity of 6-Hydroxymethylacylfulvene in Combination with Irinotecan and 5-Fluorouracil in the HT29 Human Colon Tumor Xenograft Model
Open the PDF for Enhanced Antitumor Activity of 6-Hydroxymethylacylfulvene in Combination with Irinotecan and 5-Fluorouracil in the HT29 Human Colon Tumor Xenograft Model in another window